Company Overview of Aileron Therapeutics, Inc.
Aileron Therapeutics, Inc., a biopharmaceutical company, develops stapled peptide drugs. The company focuses on candidates targeting cancer, infectious, metabolic, and immune/inflammatory diseases. Its stapled peptides penetrate cells throughout the body; and modulate intracellular and extracellular protein-protein interactions, and critical control points for human diseases. The company has a strategic partnership with Roche. Aileron Therapeutics, Inc. was formerly known as Renegade Therapeutics, Inc. The company was incorporated in 2001 and is based in Cambridge, Massachusetts.
281 Albany Street
Cambridge, MA 02139
Founded in 2001
Key Executives for Aileron Therapeutics, Inc.
Founder, Chief Executive Officer, President and Director
Co-Founder and Vice President of Corporate Development
Chief Financial & Business Officer and Senior Vice President
Chief Scientific Officer and Senior Vice President of Discovery & Innovative Technologies
Senior Vice President of Research and Preclinical Development
Compensation as of Fiscal Year 2015.
Aileron Therapeutics, Inc. Key Developments
Aileron Therapeutics, Inc. Appoints Evan Lippman as Chief Financial and Business Officer
Jan 8 15
Aileron Therapeutics, Inc. announced that it has expanded its senior management team with the appointment of Evan Lippman as the company's first Chief Financial and Business Officer. Prior to joining Aileron, Mr. Lippman was Senior Vice President at EMD Serono.
Aileron Therapeutics, Inc. Announces New Appointments
Oct 29 14
Aileron Therapeutics, Inc. announced that it has expanded its senior management team with the appointment of two industry veterans. Manuel C. Aivado, M.D., Ph.D., has joined the company as Chief Medical Officer, and Donna M. Jarlenski will serve as Vice President of Clinical Operations and Program Management. As Chief Medical Officer, Dr. Aivado will be responsible for leading Aileron's global clinical development strategy and implementing the clinical development programs including ALRN-6924. As Vice President of Clinical Operations, Ms. Jarlenski, who joins Aileron from Vertex Pharmaceuticals, will be responsible for the company's clinical operations. She will serve on the senior management team at Aileron and report to Dr. Aivado. Prior to joining Aileron, Dr. Aivado served as Taiho Oncology's Vice President of Clinical Development and Pharmacovigilance. Before joining Aileron, Ms. Jarlenski served as Senior Director, Clinical Development Execution, Global Medicines Development & Affairs at Vertex Pharmaceuticals, where she was responsible for general oversight, strategic budget and resource planning, and corporate alignment of five business units.
Aileron Therapeutics, Inc. Presents at Cowen & Co. 34th Annual Health Care Conference, Mar-04-2014 04:00 PM
Mar 3 14
Aileron Therapeutics, Inc. Presents at Cowen & Co. 34th Annual Health Care Conference, Mar-04-2014 04:00 PM. Venue: Marriott Copley Place Hotel, Boston, Massachusetts, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|